|
1
|
Vogel PM, Georgiade NG, Fetter BF, Vogel
FS and McCarty KS Jr: The correlation of histologic changes in the
human breast with the menstrual cycle. Am J Pathol. 104:23–34.
1981.PubMed/NCBI
|
|
2
|
Ramakrishnan R, Khan SA and Badve S:
Morphological changes in breast tissue with menstrual cycle. Mod
Pathol. 15:1348–1356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brisken C: Progesterone signalling in
breast cancer: A neglected hormone coming into the limelight. Nat
Rev Cancer. 13:385–396. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ratajczak HV, Sothern RB and Hrushesky WJ:
Estrous influence on surgical cure of a mouse breast cancer. J Exp
Med. 168:73–83. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hrushesky WJ, Bluming AZ, Gruber SA and
Sothern RB: Menstrual influence on surgical cure of breast cancer.
Lancet. 2:949–952. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Senie RT, Rosen PP, Rhodes P and Lesser
ML: Timing of breast cancer excision during the menstrual cycle
influences duration of disease-free survival. Ann Intern Med.
115:337–342. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Badwe RA, Gregory WM, Chaudary MA,
Richards MA, Bentley AE, Rubens RD and Fentiman IS: Timing of
surgery during menstrual cycle and survival of premenopausal women
with operable breast cancer. Lancet. 337:1261–1264. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Veronesi U, Luini A, Mariani L, Del
Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G,
Raselli R, et al: Effect of menstrual phase on surgical treatment
of breast cancer. Lancet. 343:1545–1547. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saad Z, Bramwell V, Duff J, Girotti M,
Jory T, Heathcote G, Turnbull I, Garcia B and Stit L: Timing of
surgery in relation to the menstrual cycle in premenopausal women
with operable breast cancer. Br J Surg. 81:217–220. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saad Z, Vincent M, Bramwell V, Stitt L,
Duff J, Girotti M, Jory T, Heathcote G, Turnbull I and Garcia B:
Timing of surgery influences survival in receptor-negative as well
as receptor-positive breast cancer. Eur J Cancer. 30A:1348–1352.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
von Minckwitz G, Kaufmann M, Dobberstein
S, Grischke EM and Diel IJ: Surgical procedure can explain varying
influence of menstrual cycle on prognosis of premenopausal breast
cancer patients. Breast. 4:29–32. 1995. View Article : Google Scholar
|
|
12
|
Mohr PE, Wang DY, Gregory WM, Richards MA
and Fentiman IS: Serum progesterone and prognosis in operable
breast cancer. Br J Cancer. 73:1552–1555. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kucuk AI and Atalay C: The relationship
between surgery and phase of the menstrual cycle affects survival
in breast cancer. J Breast Cancer. 15:434–440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Milella M, Nisticò C, Ferraresi V, Vaccaro
A, Fabi A, D'Ottavio AM, Botti C, Giannarelli D, Lopez M, Cortesi
E, et al: Breast cancer and timing of surgery during menstrual
cycle: A 5-year analysis of 248 premenopausal women. Breast Cancer
Res Treat. 55:259–266. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Corder AP, Cross M, Julious SA, Mullee MA
and Taylor I: The timing of breast cancer surgery within the
menstrual cycle. Postgrad Med J. 70:281–284. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Wang Y, Zhou L, Yin K, Yin W and Lu
J: Prognostic effect of menstrual cycle on timing of surgery in
premenopausal breast cancer patients. Am J Surg. 210:506–511. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wobbes T, Thomas CM, Segers MF, Peer PG,
Bruggink ED and Beex LV: The phase of the menstrual cycle has no
influence on the disease-free survival of patients with mammary
carcinoma. Br J Cancer. 69:599–600. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Badwe RA, Wang DY, Gregory WM, Fentiman
IS, Chaudary MA, Smith P, Richards MA and Rubens RD: Serum
progesterone at the time of surgery and survival in women with
premenopausal operable breast cancer. Eur J Cancer. 30A:445–448.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Holli K, Isola J and Hakama M: Prognostic
effect of timing of operation in relation to menstrual phase of
breast cancer patient-fact or fallacy. Br J Cancer. 71:124–127.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grant CS, Ingle JN, Suman VJ, Dumesic DA,
Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, et
al: Menstrual cycle and surgical treatment of breast cancer:
Findings from the NCCTG N9431 study. J Clin Oncol. 27:3620–3626.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thorpe H, Brown SR, Sainsbury JR, Perren
TJ, Hiley V, Dowsett M, Nejim A and Brown JM: Timing of breast
cancer surgery in relation to menstrual cycle phase: no effect on
3-year prognosis: The ITS study. Br J Cancer. 98:39–44. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pujol P, Daures JP, Brouillet JP, Chang S,
Rouanet P, Bringer J, Grenier J and Maudelonde T: A prospective
prognostic study of the hormonal milieu at the time of surgery in
premenopausal breast carcinoma. Cancer. 91:1854–1861. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nomura Y, Kataoka A, Tsutsui S, Murakami S
and Takenaka Y: Lack of correlation between timing of surgery in
relation to the menstrual cycle and prognosis of premenopausal
patients with early breast cancer. Eur J Cancer. 35:1326–1330.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Holmberg L, Nordén T, Lindgren A, Wide L,
Degerman M and Adami HO: Pre-operative oestradiol levels-relation
to survival in breast cancer. Eur J Surg Oncol. 27:152–156. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ben-Eliyahu S, Page GG, Shakhar G and
Taylor AN: Increased susceptibility to metastasis during
pro-oestrus/oestrus in rats: Possible role of oestradiol and
natural killer cells. Br J Cancer. 74:1900–1907. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takeda Y, Nonaka Y, Yanagie H, Yoshizaki I
and Eriguchi M: Correlation between timing of surgery in relation
to the menstrual cycle and prognosis of premenopausal breast cancer
patients. Biomed Pharmacother. 55 (Suppl 1):133s–137s. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vanek VW, Kadivar TF and Bourguet CC:
Correlation of menstrual cycle at time of breast cancer surgery to
disease-free and overall survival. South Med J. 90:780–788. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Badwe RA, Mittra I and Havaldar R: Timing
of surgery during the menstrual cycle and prognosis of breast
cancer. J Biosci. 25:113–120. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lemon HM and Rodriguez-Sierra JF: Timing
of breast cancer surgery during the luteal menstrual phase may
improve prognosis. Nebr Med J. 81:110–115. 1996.PubMed/NCBI
|
|
30
|
Mondini G, Decian F, Sorice G, Friedman D,
Spirito C, Costantini M, Sormani MP and Civalleri D: Timing of
surgery related to menstrual cycle and prognosis of premenopausal
women with breast cancer. Anticancer Res. 17:787–790.
1997.PubMed/NCBI
|
|
31
|
Klonoff-Cohen H, An R, Fries T, Le J and
Matt GE: Timing of breast cancer surgery, menstrual phase, and
prognosis: Systematic review and meta-analysis. Crit Rev Oncol
Hematol. 102:1–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chaudhry A, Puntis ML, Gikas P and Mokbel
K: Does the timing of breast cancer surgery in pre-menopausal women
affect clinical outcome? An update. Int Semin Surg Oncol. 3:372006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kroman N: Timing of breast cancer surgery
in relation to the menstrual cycle-the rise and fall of a
hypothesis. Acta Oncol. 47:576–579. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Samuel M, Wai KL, Brennan VK and Yong WS:
Timing of breast surgery in premenopausal breast cancer patients.
Cochrane Database Syst Rev. CD0037202011.PubMed/NCBI
|
|
35
|
Sherman BM and Korenman SG: Hormonal
characteristics of the human menstrual cycle throughout
reproductive life. J Clin Invest. 55:699–706. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McGuire WL, Hilsenbeck S and Clark GM:
Optimal mastectomy timing. J Natl Cancer Inst. 84:346–348. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
McGuire WL: The optimal timing of
mastectomy: Low tide or high tide? Ann Intern Med. 115:401–403.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Badwe R, Hawaldar R, Parmar V, Nadkarni M,
Shet T, Desai S, Gupta S, Jalali R, Vanmali V, Dikshit R and Mittra
I: Single-injection depot progesterone before surgery and survival
in women with operable breast cancer: A randomized controlled
trial. J Clin Oncol. 29:2845–2851. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sanchez AM, Flamini MI, Zullino S, Russo
E, Giannini A, Mannella P, Naccarato AG, Genazzani AR and Simoncini
T: Regulatory actions of LH and follicle-stimulating hormone on
breast cancer cells and mammary tumors in rats. Front Endocrinol
(Lausanne). 9:2392018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sanchez AM, Flamini MI, Russo E, Casarosa
E, Pacini S, Petrini M, Genazzani AR and Simoncini T: LH and FSH
promote migration and invasion properties of a breast cancer cell
line through regulatory actions on the actin cytoskeleton. Mol Cell
Endocrinol. 437:22–234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Silva EG, Mistry D, Li D, Kuerer HM,
Atkinson EN, Lopez AN, Shannon R and Hortobagyi GN: Elevated
luteinizing hormone in serum, breast cancer tissue, and normal
breast tissue from breast cancer patients. Breast Cancer Res Treat.
76:125–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gnant MF, Seifert M, Jakesz R, Adler A,
Mittlboeck M and Sevelda P: Breast cancer and timing of surgery
during menstrual cycle. A 5-year analysis of 385 pre-menopausal
women. Int J Cancer. 52:707–12. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schenker JG, Meirow D and Schenker E:
Stress and human reproduction. Eur J Obstet Gynecol Reprod Biol.
45:1–8. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nagma S, Kapoor G, Bharti R, Batra A,
Batra A, Aggarwal A and Sablok A: To evaluate the effect of
perceived stress on menstrual function. J Clin Diagn Res.
9:QC01–QC03. 2015.PubMed/NCBI
|
|
45
|
Atalay C, Kanliöz M and Altinok M:
Menstrual cycle and hormone receptor status in breast cancer
patients. Neoplasma. 49:2782002.PubMed/NCBI
|
|
46
|
Dowsett M, Allred C, Knox J, Quinn E,
Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, et
al: Relationship between quantitative estrogen and progesterone
receptor expression and human epidermal growth factor receptor 2
(HER-2) status with recurrence in the arimidex, tamoxifen, alone or
in combination trial. J Clin Oncol. 26:1059–1065. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Viale G, Regan MM, Maiorano E,
Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K,
Ohlschlegel C, et al: Chemoendocrine compared with endocrine
adjuvant therapies for node-negative breast cancer: Predictive
value of centrally reviewed expression of estrogen and progesterone
receptors-international breast cancer study group. J Clin Oncol.
26:1404–1410. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Oliver DJ and Ingram DM: Timing of surgery
during the menstrual cycle for breast cancer: Possible role of
growth factors. Eur J Cancer. 31A:325–328. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Balsari A, Casalini P, Tagliabue E, Greco
M, Pilotti S, Agresti R, Giovanazzi R, Alasio L, Rumio C,
Cascinelli N, et al: Fluctuation of HER2 expression in breast
carcinomas during the menstrual cycle. Am J Pathol. 155:1543–1547.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chia S, Norris B, Speers C, Cheang M,
Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO and Gelmon K:
Human epidermal growth factor receptor 2 overexpression as a
prognostic factor in a large tissue microarray series of
node-negative breast cancers. J Clin Oncol. 26:5697–5704. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ,
Kim JH, Kim SW, Ryu HS, Park IA, Im SA, et al: Prognostic and
predictive values of EGFR overexpression and EGFR copy number
alteration in HER2-positive breast cancer. Br J Cancer.
112:103–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gompel A, Martin A, Simon P, Schoevaert D,
Plu-Bureau G, Hugol D, Audouin J, Leygue E, Truc JB and Poitout P:
Epidermal growth factor receptor and c-erbB-2 expression in normal
breast tissue during the menstrual cycle. Breast Cancer Res Treat.
38:227–235. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sainsbury JR, Farndon JR, Needham GK,
Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status
as predictor of early recurrence of and death from breast cancer.
Lancet. 1:1398–1402. 1987.PubMed/NCBI
|
|
54
|
Need EF, Selth LA, Trotta AP, Leach DA,
Giorgio L, O'Loughlin MA, Smith E, Gill PG, Ingman WV, Graham JD
and Buchanan G: The unique transcriptional response produced by
concurrent estrogen and progesterone treatment in breast cancer
cells results in upregulation of growth factor pathways and
switching from a Luminal A to a Basal-like subtype. BMC Cancer.
15:7912015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bernhardt SM, Dasari P, Walsh D, Townsend
AR, Price TJ and Ingman WV: Hormonal modulation of breast cancer
gene expression: Implications for intrinsic subtyping in
premenopausal women. Front Oncol. 6:2412016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bernhardt SM, Dasari P, Glynn DJ, Woolford
L, Raymond W, Moldenhauer LM, Walsh D, Townsend AR, Price TJ and
Ingman WV: Abstract P1-10-12: Menstrual cycling critically affects
the Oncotype DX 21-gene signature: implications for predictive
biomarker assays in premenopausal women. Cancer Res. 80:P1-10-12.
2020.
|
|
57
|
McCulloch P, Choy A and Martin L:
Association between tumour angiogenesis and tumour cell shedding
into effluent venous blood during breast cancer surgery. Lancet.
346:1334–1335. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hu XC and Chow LW: Fine needle aspiration
may shed breast cells into peripheral blood as determined by
RT-PCR. Oncology. 59:217–222. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Juratli MA, Siegel ER, Nedosekin DA,
Sarimollaoglu M, Jamshidi-Parsian A, Cai C, Menyaev YA, Suen JY,
Galanzha EI and Zharov VP: In vivo long-term monitoring of
circulating tumor cells fluctuation during medical interventions.
PLoS One. 10:e01376132015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mathenge EG, Dean CA, Clements D,
Vaghar-Kashani A, Photopoulos S, Coyle KM, Giacomantonio M, Malueth
B, Nunokawa A, Jordan J, et al: Core needle biopsy of breast cancer
tumors increases distant metastases in a mouse model. Neoplasia.
16:950–960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Horowitz M, Neeman E, Sharon E and
Ben-Eliyahu S: Exploiting the critical perioperative period to
improve long-term cancer outcomes. Nat Rev Clin Oncol. 12:213–226.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fentiman IS: 12. Timing of surgery for
breast cancer. Int J Clin Pract. 56:188–190. 2002.PubMed/NCBI
|
|
63
|
Garvin S and Dabrosin C: Tamoxifen
inhibits secretion of vascular endothelial growth factor in breast
cancer in vivo. Cancer Res. 63:8742–8748. 2003.PubMed/NCBI
|
|
64
|
Garvin S, Nilsson UW, Huss FR, Kratz G and
Dabrosin C: Estradiol increases VEGF in human breast studied by
whole-tissue culture. Cell Tissue Res. 325:245–251. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Heer K, Kumar H, Speirs V, Greenman J,
Drew PJ, Fox JN, Carleton PJ, Monson JR and Kerin MJ: Vascular
endothelial growth factor in premenopausal women-indicator of the
best time for breast cancer surgery? Br J Cancer. 78:1203–1207.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Saad Z, Bramwell VH, Wilson SM, O'Malley
FP, Jeacock J and Chambers AF: Expression of genes that contribute
to proliferative and metastatic ability in breast cancer resected
during various menstrual phases. Lancet. 351:1170–1173. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Oesterreich S, Deng W, Jiang S, Cui X,
Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J and Lee AV:
Estrogen-mediated down-regulation of E-cadherin in breast cancer
cells. Cancer Res. 63:5203–5208. 2003.PubMed/NCBI
|
|
68
|
Rochefort H, Augereau P, Briozzo P, Capony
F, Cavailles V, Freiss G, Garcia M, Maudelonde T, Morisset M and
Vignon F: Structure, function, regulation and clinical significance
of the 52K pro-cathepsin D secreted by breast cancer cells.
Biochimie. 70:943–949. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Arruvito L, Sanz M, Banham AH and Fainboim
L: Expansion of CD4+ CD25+ and
FOXP3+ regulatory T cells during the follicular phase of
the menstrual cycle: Implications for human reproduction. J
Immunol. 178:2572–2578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Prieto GA and Rosenstein Y: Oestradiol
potentiates the suppressive function of human CD4 CD25 regulatory T
cells by promoting their proliferation. Immunology. 118:58–65.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lee JH, Ulrich B, Cho J, Park J and Kim
CH: Progesterone promotes differentiation of human cord blood fetal
T cells into T regulatory cells but suppresses their
differentiation into Th17 cells. J Immunol. 187:1778–1787. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chua AC, Hodson LJ, Moldenhauer LM,
Robertson SA and Ingman WV: Dual roles for macrophages in ovarian
cycle-associated development and remodelling of the mammary gland
epithelium. Development. 137:4229–4238. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hodson LJ, Chua AC, Evdokiou A, Robertson
SA and Ingman WV: Macrophage phenotype in the mammary gland
fluctuates over the course of the estrous cycle and is regulated by
ovarian steroid hormones. Biol Reprod. 89:652013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mackay IR, Goodyear MD, Riglar C and
Penschow J: Effect on natural killer and antibody-dependent
cellular cytotoxicity of adjuvant cytotoxic chemotherapy including
melphalan in breast cancer. Cancer Immunol Immunother. 16:98–100.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hrushesky WJ, Gruber SA, Sothern RB,
Hoffman RA, Lakatua D, Carlson A, Cerra F and Simmons RL: Natural
killer cell activity: Age, estrous- and circadian-stage dependence
and inverse correlation with metastatic potential. J Natl Cancer
Inst. 80:1232–1237. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hanna N and Schneider M: Enhancement of
tumor metastasis and suppression of natural killer cell activity by
beta-estradiol treatment. J Immunol. 130:974–980. 1983.PubMed/NCBI
|
|
77
|
Berry J, Green BJ and Matheson DS:
Modulation of natural killer cell activity by tamoxifen in stage I
post-menopausal breast cancer. Eur J Cancer Clin Oncol. 23:517–520.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Dasari P, Sharkey DJ, Noordin E, Glynn DJ,
Hodson LJ, Chin PY, Evdokiou A, Robertson SA and Ingman WV:
Hormonal regulation of the cytokine microenvironment in the mammary
gland. J Reprod Immunol. 106:58–66. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Clarke RB, Howell A and Anderson E: Type I
insulin-like growth factor receptor gene expression in normal human
breast tissue treated with oestrogen and progesterone. Br J Cancer.
75:251–257. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Dabrosin C: Increase of free insulin-like
growth factor-1 in normal human breast in vivo late in the
menstrual cycle. Breast Cancer Res Treat. 80:193–198. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Papa V, Hartmann KK, Rosenthal SM, Maddux
BA, Siiteri PK and Goldfine ID: Progestins induce down-regulation
of insulin-like growth factor-I (IGF-I) receptors in human breast
cancer cells: Potential autocrine role of IGF-II. Mol Endocrinol.
5:709–717. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Belkaid Y and Hand TW: Role of the
microbiota in immunity and inflammation. Cell. 157:121–141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Rosean CB, Bostic RR, Ferey JCM, Feng T,
Azar FN, Tung KS, Dozmorov MG, Smirnova E, Bos PD and Rutkowski MR:
Preexisting commensal dysbiosis is a host-intrinsic regulator of
tissue inflammation and tumor cell dissemination in hormone
receptor-positive breast cancer. Cancer Res. 79:3662–3675. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Flores R, Shi J, Fuhrman B, Xu X, Veenstra
TD, Gail MH, Gajer P, Ravel J and Goedert JJ: Fecal microbial
determinants of fecal and systemic estrogens and estrogen
metabolites: A cross-sectional study. J Transl Med. 10:2532012.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Fuhrman BJ, Feigelson HS, Flores R, Gail
MH, Xu X, Ravel J and Goedert JJ: Associations of the fecal
microbiome with urinary estrogens and estrogen metabolites in
postmenopausal women. J Clin Endocrinol Metab. 99:4632–4640. 2014.
View Article : Google Scholar : PubMed/NCBI
|
